UCLA rapamycin autism mouse study

In late July 2026, UCLA Health researchers reported that a single short‑term dose of the immunosuppressant rapamycin rapidly mitigated autism‑like brain overactivity, seizure risk, sensory sensitivity, and repetitive behaviors in adult mice that had been exposed to maternal inflammation. The initial report highlighted the speed of the effect—observable within hours—and noted that the benefits were fleeting, disappearing after about three days, with repeated dosing quickly losing efficacy and raising toxicity concerns.

A follow‑up release a few days later reiterated these findings, emphasizing that rapamycin itself is unsuitable for human therapy. The researchers called for the development of safer compounds that can modulate the mTOR signaling pathway and functional neuronal circuits without the adverse effects seen with rapamycin.